Stereotaxis, Inc. (STXS) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the interventional laboratory, primarily focusing on Robotic Magnetic Navigation (RMN) for cardiac ablation procedures. The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $6.29 million | $7.47 million |
| Gross Margin | $3.79 million (60.3%) | $4.06 million (54.4%) |
| Operating Loss | $(5.98) million | $(5.93) million |
| Net Loss | $(5.86) million | $(5.82) million |
| Net Loss Attributable to Common Stockholders | $(6.17) million | $(6.14) million |
| Cash and Cash Equivalents (End of Period) | $14.62 million | $10.69 million |
| Working Capital | $12.94 million | N/A |
| Debt | $0 | $0 |
Note: All figures in millions unless otherwise noted. The company reported no debt as of March 31, 2026.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 16% year-over-year. System revenue dropped 33% ($1.32M vs $1.96M) due to lower sales volume. Disposables, service, and accessories revenue declined 10% ($4.97M vs $5.51M), attributed to the transition from Johnson & Johnson catheters to the proprietary MAGiC catheter.
- Margin Expansion: Despite lower revenue, gross margin percentage improved to 60% from 54%, driven by a favorable change in product mix.
- Expense Management: Sales and marketing expenses decreased 17% ($2.62M vs $3.15M) due to lower headcount costs. General and administrative expenses increased 6% ($4.76M vs $4.50M), primarily due to a $0.76M loss on the revaluation of contingent consideration related to the APT acquisition and costs associated with the pending Robocath acquisition.
- Liquidity: Cash balances increased by $1.2 million during the quarter, supported by $4.8 million in gross proceeds from an at-the-market (ATM) equity offering.
Guidance, Outlook, and Risks
- Acquisition Activity: On April 14, 2026, the company entered into an agreement to acquire Robocath, a French innovator in mechanical robotic technology, for $20.0 million upfront plus up to $25.0 million in contingent consideration. Closing is expected by Q3 2026.
- Regulatory Milestones: The company received FDA 510(k) clearance for the GenesisX RMN System (Q4 2025) and the MAGiC catheter (January 2026). The MAGiC Sweep catheter received FDA clearance in July 2025.
- Capital Resources: The company maintains an ATM facility with Roth Capital Markets for up to $50.0 million. As of March 31, 2026, the full $50.0 million remained available. Management believes current cash resources are sufficient to fund operations for the foreseeable future but may require additional funding.
- Risks and Contingencies:
- Tariffs: New U.S. tariffs (10% under Section 122) and "tariff stacking" on specialty alloys could impact costs, particularly for the MAGiC catheter manufactured in Germany.
- Supply Chain: Ongoing transition from J&J catheters to proprietary MAGiC catheters creates supply uncertainty.
- Litigation: The company has recorded $4.3 million in insurance receivables and $4.3 million in accrued legal liabilities related to ongoing litigation.
Investor Verification Checklist
- ATM Offering Utilization: Verify the pace of share issuance under the $50M ATM facility and its dilutive impact on existing shareholders.
- Robocath Acquisition: Monitor the closing timeline and integration costs of the Robocath acquisition announced in April 2026.
- Catheter Transition: Assess the ramp-up of MAGiC catheter production and the potential revenue gap during the transition away from J&J supplied catheters.
- Tariff Impact: Evaluate the specific cost impact of new U.S. tariffs on imported components and the MAGiC catheter.
- Cash Burn Rate: Review the trajectory of operating cash burn ($3.44M in Q1) against current cash reserves ($14.62M) to determine runway.